Something historic began in early 2026 in a Boston laboratory — and its ripple effects could eventually reach every American who dreads the physical decline of aging.
Life Biosciences, a biotechnology company co-founded by Harvard genetics professor Dr. David Sinclair, announced on January 28, 2026, that the U.S. Food and Drug Administration cleared its Investigational New Drug application for a therapy called ER-100 — making it the first cellular rejuvenation treatment using partial epigenetic reprogramming ever cleared for testing in human beings.
